Striae Distensae and an Innovative Intradermal Medical Device Based on PN HPT™, Hyaluronic Acid, and Mannitol. A Real-World Insight

Introduction: Striae distensae are often more than a mere skin aesthetic trouble for their impact on self-esteem and as signals of internal medicine disorders like hypercortisolism or cachexia. There is a need to advance in treating striae distensae effectively, particularly their late atrophic hypochromic stage. PN HPT™ may help to restore and preserve a physiologically sound dermal environment. The paper reports the outcomes of a survey study based on an anonymous questionnaire. The study’s purpose was to confirm the long-term effectiveness and safety profile of an intradermal medical device based on PN HPT™ (1 mg/mL), HA (1 mg/mL), and mannitol ) within a multi-year clinical monitoring program. Methods: The investigators — dermatologists and plastic and aesthetic surgeons — carried out the study in real-world subjects, all of them women, who spontaneously sought office treatment to improve skin quality in areas of subjectively grievous striae distensae and striae albae—a total of 38 lesions. All investigators had already used the investigated intradermal device for short-term treatment and long-term maintenance. All surveyed subjects had undergone a cycle of six to eight intradermal injection sessions over three months to improve the texture of their striae distensae—a once-weekly injection for the first month and one injection every two weeks for the last two months with a tolerance of two missing injections. Assessment tools and timing: Global Improvement Scale (GIS) and Global Aesthetic Improvement Scale (GAIS) two to four weeks after the end of the treatment period. Results: At the follow-up visit, the investigators evaluated that, globally (mean GIS scores), 50.0% and 47.4% of the treated striae distensae showed moderate improvement or were much improved compared with the baseline. The corresponding outcomes for the independent evaluator were 55.3% and 44.7%. The local skin quality and texture in the lesion areas (mean GAIS scores) appeared to have improved or to be much improved by 50.0% and 50.0% according to investigators, and by 42.9% and 57.1%, respectively, according to surveyed patients, with no reported side effects. Conclusion: The real-world monitoring survey demonstrated that the NEWST ONE medical device based on PN HPT™, HA, and mannitol as an inhibitor of HA metabolism retains its long-standing record of efficient performance and excellent safety with no variations over time.